David Sinclair Longevity Protocol: A Clinical Interpretation

Who Is David Sinclair and Why Does His Protocol Matter?

David Sinclair holds a PhD from the University of New South Wales and has been a tenured professor at Harvard Medical School since 2005. His lab has published over 200 peer-reviewed papers on aging biology, sirtuin pathways, and NAD+ metabolism. His 2019 book "Lifespan: Why We Age and Why We Don't Have To" sold widely and brought concepts like NAD+ precursors and sirtuin activators into mainstream conversation.

His protocol matters clinically not because he is a celebrity, but because millions of people now take the same compounds based on his public statements. Physicians are fielding questions about NMN, resveratrol, and off-label metformin from patients who have never been diagnosed with diabetes or metabolic disease. Getting the evidence right has direct consequences for those patients.

What Sinclair Has Actually Said

Sinclair has disclosed his regimen across multiple platforms, including the Huberman Lab podcast (2022), his own Lifespan Podcast, and interviews with publications including The New York Times. His disclosures include 1 g/day NMN taken in the morning, 1 g/day resveratrol dissolved in yogurt or olive oil to improve absorption, 800 mg/day metformin taken at night (skipping the dose before intense exercise), and intermittent rapamycin dosing at approximately 5-6 mg once weekly.

He has been explicit that this is self-experimentation. In a 2023 interview he stated, "I'm not recommending this for everyone. I'm a scientist who is running an experiment on one person, which is myself." This distinction matters when translating his protocol into clinical guidance.

The Conflict-of-Interest Context

Sinclair co-founded the company Jumpstart Fertility and holds equity in companies connected to NMN and sirtuin research. This does not disqualify his science, but it is a relevant disclosure. The 2013 paper from his lab in Cell showing that NMN restored vascular function and muscle endurance in aged mice generated significant commercial activity before human RCT data were available.

NMN and NAD+ Biology: What the Evidence Shows

NMN (nicotinamide mononucleotide) is a biosynthetic precursor to NAD+ (nicotinamide adenine dinucleotide). NAD+ levels decline with age in humans, and that decline has been measured in skeletal muscle, blood, and liver tissue. The biological case for supplementing NAD+ precursors is grounded in real biochemistry.

Preclinical Data

Animal studies are genuinely compelling. A 2013 study published in Cell (Gomes et al.) found that one week of NMN administration in aged mice restored NAD+ levels and improved mitochondrial function to levels comparable to younger animals (1). A 2016 study in Cell Metabolism found NMN supplementation improved muscle function, energy metabolism, and lifespan in mice (2). These are not trivial findings. They drove the rationale for human trials.

Human RCT Data

Human data are more limited. A 2021 randomized, placebo-controlled trial (N=25 healthy adults, aged 65 and older) published in Nature Aging found that 250 mg/day oral NMN for 10 weeks raised NAD+ levels in blood by approximately 38% and improved muscle insulin sensitivity, but did not produce changes in body weight, VO2 max, or lipid profiles (3). The sample size was small and the duration was short. A separate 2022 trial (N=30) published in NPJ Aging found no significant effect of NMN on physical performance measures compared to placebo (4).

The honest summary: NMN reliably raises blood NAD+ levels in humans. Whether that biochemical change produces meaningful health outcomes has not been established in trials adequately powered to detect them.

Dosing and Safety

Sinclair takes 1 g/day. The trials cited above used 250-500 mg/day. No serious adverse events have been reported at doses up to 1,200 mg/day in single-dose safety studies. Long-term safety data in humans do not yet exist beyond 12 months of continuous use.

Resveratrol: The Sirtuin Activator That Has Not Cleared Human Trials

Resveratrol is a polyphenol found in red wine and grape skins. Sinclair's lab produced foundational research showing resveratrol activates SIRT1, a NAD+-dependent deacetylase involved in cellular stress responses and mitochondrial biogenesis.

The Science Behind the Hypothesis

A 2003 Nature paper from Sinclair's group (Howitz et al.) showed resveratrol activated Sir2 (the yeast ortholog of SIRT1) and extended yeast lifespan by up to 70% (5). Follow-up work in mice showed high-dose resveratrol protected against the negative metabolic effects of a high-fat diet. These papers generated enormous scientific excitement.

Where Human Trials Diverged

Human trials have not replicated the major outcomes. A 2012 randomized trial in obese men (N=24) published in Cell Metabolism found resveratrol supplementation at 150 mg/day improved some metabolic markers, but a 2014 trial (N=119, older adults) published in JAMA Internal Medicine found resveratrol 500 mg/day had no effect on inflammatory biomarkers or cardiovascular outcomes and was associated with worse outcomes on some measures (6). A Cochrane review of resveratrol and cardiovascular outcomes found insufficient evidence to support routine use (7).

Sinclair's rationale for taking resveratrol with a fat source (yogurt or olive oil) is pharmacokinetically sound. Oral bioavailability of resveratrol is poor due to rapid first-pass hepatic metabolism. Co-administration with fat may improve absorption, but this has not been shown to restore clinical efficacy in trials.

Metformin: The Most Evidence-Backed Compound in the Stack

Of all the agents Sinclair takes, metformin carries the strongest and longest human evidence base, though that evidence base is in type 2 diabetes, not healthy aging.

Established Mechanisms

Metformin activates AMPK (AMP-activated protein kinase), inhibits mitochondrial complex I, reduces hepatic glucose production, and has downstream effects on mTOR signaling. All of these pathways are implicated in aging biology. Observational data from diabetic patients have repeatedly shown metformin users live longer than diabetic non-users, and in several analyses, longer than age-matched non-diabetic controls not taking metformin.

TAME Trial: The Definitive Test

The Targeting Aging with Metformin (TAME) trial, funded by the American Federation for Aging Research and approved by the FDA as a longevity trial endpoint (the first such approval), is testing 1,500 mg/day metformin versus placebo in approximately 3,000 adults aged 65-79 across 14 clinical sites. The primary composite endpoint is time to first occurrence of a major age-related condition including cardiovascular disease, cancer, dementia, and death. Results are not expected until approximately 2027 (8).

Clinical Nuance for Non-Diabetic Use

Metformin may blunt the anabolic response to resistance exercise. A randomized trial (N=139) published in Aging Cell in 2019 found that metformin partially attenuated the increase in skeletal muscle mass and VO2 max gained through exercise in older adults (9). Sinclair's reported practice of skipping metformin before intense training sessions reflects awareness of this finding, not simply personal preference. Prescribing metformin off-label for longevity in non-diabetic patients requires informed consent about this trade-off, as well as monitoring for vitamin B12 depletion, which occurs in roughly 10-30% of long-term users.

Rapamycin: The Most Potent and Least Understood Agent

Rapamycin (sirolimus) is an FDA-approved immunosuppressant used to prevent organ transplant rejection and treat certain cancers. Its mechanism, inhibition of mTOR complex 1 (mTORC1), is one of the most reproducible longevity interventions in model organisms.

Animal Evidence Is Striking

The Interventions Testing Program (ITP), a rigorous multi-site NIA-funded trial in mice, found that rapamycin extended median lifespan by 9-14% in male mice and 13-21% in female mice, even when started in mice equivalent to 60 human years of age (10). These are among the strongest single-agent longevity findings in mammals.

Human Risks Are Real

Rapamycin is not approved for longevity use. Known side effects at immunosuppressive doses include impaired wound healing, hyperlipidemia, thrombocytopenia, mouth sores, and increased susceptibility to infection. Whether lower intermittent doses, as Sinclair reportedly uses, carry a meaningfully lower risk profile is not established by clinical trials. A 2014 study in Science Translational Medicine (N=218 elderly adults) found that a rapamycin analog (RAD001) at low dose improved response to influenza vaccine by approximately 20%, suggesting some immune benefits at sub-immunosuppressive doses (11). That is a single study with a narrow endpoint.

Any physician considering off-label rapamycin prescribing should review the FDA label, establish baseline lipid panels, CBC, and renal function, and document a detailed informed consent process. Prescribing rapamycin for longevity to otherwise healthy adults without this structure exposes both the patient and the prescriber to meaningful risk.

Additional Compounds Sinclair Has Mentioned

Beyond the core four agents, Sinclair has mentioned several other compounds at various times.

Vitamin D3 and K2

Sinclair has reported taking 4,000-5,000 IU of vitamin D3 daily with vitamin K2. This is consistent with guidance from the Endocrine Society for correcting deficiency but exceeds the 600-800 IU recommended daily allowance for adults under 70 set by the National Academies. Vitamin D sufficiency (serum 25-OH-D above 30 ng/mL) is associated with reduced all-cause mortality in observational data, but supplementation trials in vitamin D-sufficient individuals have not consistently shown benefit (12).

Quercetin and Fisetin

Both are considered senolytic candidates, meaning they may selectively clear senescent cells that accumulate with age and drive inflammation. A Mayo Clinic pilot study (N=14, idiopathic pulmonary fibrosis patients) found that a 3-day course of dasatinib plus quercetin reduced senescent cell burden in adipose tissue (13). This is early-phase data in a disease population. Applying it to healthy aging is inferential at this stage.

Statin Use

Sinclair has mentioned taking a low-dose statin, consistent with cardiovascular risk management guidelines rather than longevity-specific rationale. The ACC/AHA 2019 Primary Prevention Guidelines recommend statin therapy for adults aged 40-75 with a 10-year atherosclerotic cardiovascular disease risk above 10% (14).

Original HealthRX Clinical Readiness Framework

The following framework gives clinicians a structured way to evaluate each compound in Sinclair's stack against four dimensions: mechanism quality, animal evidence strength, human RCT evidence, and known safety signal in healthy adults. Each dimension is scored 1-3.

| Compound | Mechanism Quality | Animal Evidence | Human RCT Evidence | Safety in Healthy Adults | Total (12 max) | |---|---|---|---|---|---| | Metformin | 3 | 3 | 2 (diabetic populations) | 2 (B12 depletion, exercise blunting) | 10 | | NMN | 3 | 3 | 1 (small, short trials) | 3 (no serious signals to date) | 10 | | Rapamycin | 3 | 3 | 1 (single analog trial) | 1 (immunosuppressive risk profile) | 8 | | Resveratrol | 2 | 2 | 1 (human trials negative) | 3 (well-tolerated) | 8 | | Fisetin/Quercetin | 2 | 2 | 1 (disease populations only) | 2 (limited data) | 7 | | Vitamin D3 | 2 | 1 | 2 (mixed supplementation trials) | 2 (toxicity above 10,000 IU/day) | 7 |

Scores above 9 indicate a compound with sufficient biological rationale and safety signal to warrant a clinician-supervised trial. Scores of 7-8 indicate promising but premature candidates for routine clinical prescription. Scores below 7 indicate insufficient evidence for clinical recommendation outside of a formal research protocol.

What Physicians Should Tell Patients Asking About This Protocol

Patients arrive at telehealth consultations with printed supplement lists, podcast timestamps, and a sincere desire to slow aging. Dismissing the entire category does not serve them. Treating everything as established medicine does not serve them either.

The Tiered Conversation

A useful approach separates the compounds by evidence tier. Metformin has the strongest case for a clinical conversation in older, non-diabetic adults, particularly once TAME results are available. NMN supplementation carries a low risk profile and a plausible mechanism, making it reasonable to discuss in the context of informed consent and realistic expectations. Rapamycin should not be prescribed off-label for longevity outside of a research setting given its known immunosuppressive effects. Resveratrol at 1 g/day is unlikely to cause harm but the evidence for benefit is weak enough that it should not be framed as an established intervention.

Monitoring Recommendations

Patients already taking these compounds without physician oversight should be assessed for: serum B12 (metformin users), fasting glucose and HbA1c (metformin users), lipid panel and CBC (rapamycin users), serum 25-OH-D (vitamin D users), and renal function (metformin and rapamycin users). These are standard labs, not novel tests, and they provide a safety baseline.

Setting Appropriate Expectations

No human trial has shown that any of these compounds extends lifespan in healthy adults. The biological mechanisms are real and the animal data are often impressive. But the gap between a compelling mechanism and a proven clinical outcome is where most longevity interventions have historically stalled. Patients deserve to understand this gap in plain language before beginning any regimen.

The American College of Physicians has stated that clinicians should communicate uncertainty honestly and avoid implying that preliminary evidence establishes clinical benefit (15).

The Broader Longevity Field: Where Evidence Is Heading

Sinclair's protocol reflects a broader shift in aging research from treating individual diseases to targeting the underlying biology of aging itself. The FDA's acceptance of the TAME trial's aging composite endpoint was a regulatory milestone because it acknowledged, for the first time, that "aging" could be treated as a drug target (8).

Several other trials are active. The PEARL trial is testing NMN in older adults with a larger sample size than prior studies. Multiple academic centers are running phase 1 and phase 2 rapamycin trials in healthy older adults under IRB oversight. The geroscience field, as defined by the National Institute on Aging, is receiving record funding with the explicit goal of compressing morbidity rather than simply extending lifespan.

Sinclair's public profile has accelerated public interest in this field by years, possibly a decade. The clinical challenge is managing the gap between that accelerated interest and the pace at which controlled trial data can responsibly validate it.